Paul Goode - 25 Mar 2025 Form 4 Insider Report for Glucotrack, Inc. (GCTK)

Role: Chief Executive Officer, Director
Signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Issuer symbol: GCTK
Transactions as of: 25 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 07 Oct 2025, 19:26:08 UTC
Previous filing: 03 Jul 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Goode Paul	Chief Executive Officer, Director	C/O GLUCOTRACK, INC., 301 RTE. 17 NORTH, SUITE 800, RUTHERFORD	/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact	07 Oct 2025	0001622251

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GCTK	Common Stock, par value $0.001 per share	Other		+42	+14%		339	25 Mar 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with Glucotrack, Inc. (the "Issuer"), pursuant to which the reporting person is entitled to certain specified milestone payments, payable in common stock, par value $0.001 per share, of the Issuer (the "Common Stock"), as set forth in the IP Purchase Agreement. Upon the achievement of the third milestone contemplated by the IP Purchase Agreement, the reporting person was issued 42 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

Content

On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with Glucotrack, Inc. (the "Issuer"), pursuant to which the reporting person is entitled to certain specified milestone payments, payable in common stock, par value $0.001 per share, of the Issuer (the "Common Stock"), as set forth in the IP Purchase Agreement. Upon the achievement of the third milestone contemplated by the IP Purchase Agreement, the reporting person was issued 42 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

Remarks:

On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's Common Stock was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "February 2025 Reverse Split"), and on June 13, 2025, a 1-for-60 reverse stock split of the Common Stock was implemented (the "June 2025 Reverse Stock Split", and together with the 2024 Reverse Split and the February 2025 Reverse Stock Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.